Compare WM & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WM | SNY |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.9B | 116.8B |
| IPO Year | 2002 | N/A |
| Metric | WM | SNY |
|---|---|---|
| Price | $238.44 | $43.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 6 |
| Target Price | ★ $253.95 | $61.50 |
| AVG Volume (30 Days) | 2.2M | ★ 4.2M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | 1.58% | ★ 3.66% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.70 | N/A |
| Revenue | ★ $14,485,000,000.00 | N/A |
| Revenue This Year | $8.26 | $3.01 |
| Revenue Next Year | $5.42 | $5.80 |
| P/E Ratio | $35.74 | ★ $6.14 |
| Revenue Growth | ★ 6.44 | N/A |
| 52 Week Low | $194.11 | $43.51 |
| 52 Week High | $248.13 | $59.17 |
| Indicator | WM | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 31.35 |
| Support Level | $213.90 | N/A |
| Resistance Level | $239.70 | $48.97 |
| Average True Range (ATR) | 4.46 | 0.69 |
| MACD | -0.66 | -0.35 |
| Stochastic Oscillator | 53.99 | 2.66 |
WM, previously known as Waste Management, ranks as the largest integrated provider of traditional solid waste services in the United States, operating 262 active landfill sites and about 339 transfer stations that help with transporting waste efficiently and economically. The company serves residential, commercial, industrial, and medical end markets for waste collection, transfer, and disposal. The company also has an energy business emanating from the beneficial use of landfill gas and is a leading recycler in North America.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.